April 24th 2024
Ramez N. Eskander, MD, discusses overall survival data for pembrolizumab plus chemotherapy in advanced/recurrent endometrial cancer.
October 6th 2023
Closing their conversation, Ramez Eskander, MD, and Krishnansu Tewari, MD, share how they envision the future treatment landscape for patients with advanced endometrial cancer.
Key opinion leaders discuss targeted treatment regimens for advanced or recurrent endometrial cancer that are currently under development.
September 29th 2023
Krishnansu Tewari, MD, presents the profile of a 68-year-old postmenopausal woman with recurrent endometrial cancer for discussion.
Experts explain how they change their treatment strategies if a patient with advanced endometrial cancer does not respond to treatment or experiences disease progression.
September 22nd 2023
Krishnansu Tewari, MD, reviews emerging data from two studies investigating immunotherapy-based combination regimens for the first-line treatment of advanced endometrial cancer.
Krishnansu Tewari, MD, details the first-line treatment options for patients with recurrent endometrial cancer.
September 15th 2023
Ramez Eskander, MD, presents the profile of a 64-year-old postmenopausal woman diagnosed with recurrent endometrial carcinoma for discussion.
Ramez Eskander, MD, and Krishnansu Tewari, MD, provide an overview of endometrial cancer, including prevalence, staging criteria, and molecular profiling.
March 28th 2023
Ramez N. Eskander, MD, discusses findings from the phase 3 NRG GY018 trial of pembrolizumab plus chemotherapy in patients with endometrial cancer.
April 5th 2022
Experts highlight key ongoing trials and emerging therapies for patients with endometrial cancer.
March 29th 2022
Shared insight on the management of commonly observed adverse events in patients with endometrial cancer who are receiving combination lenvatinib/pembrolizumab.
A brief review of treatment interruption, discontinuation, and dose modification rates in patients receiving combination lenvatinib/pembrolizumab in the KEYNOTE-775 trial or in the experts’ clinical practice.
March 22nd 2022
Vicky Makker, MD, leads a discussion of efficacy data from the KEYNOTE-775 trial on combination lenvatinib/pembrolizumab in patients with endometrial cancer.
A comprehensive overview of first-line treatment options for patients with advanced endometrial cancer.
March 15th 2022
Experts discuss how molecular testing can inform treatment selection and patient management for those with endometrial cancer.
Vicky Makker, MD and Ramez Eskander, MD discuss the increasing global incidence of endometrial cancer.
August 25th 2021
Ramez N. Eskander, MD, discusses the utility of lymphadenectomy in patients with endometrial cancer.
February 21st 2019
Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses the need for more effective biomarkers in the treatment of patients with ovarian cancer.
February 1st 2019
Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses combination approaches with immunotherapy in ovarian cancer.